The single-dose injectable from Merck Animal Health protects against 3 swine diseases.
A novel vaccine (Circumvent CML; Merck Animal Health) against disease caused by Porcine Circovirus Types 2a (PCV2a) and 2d (PCV2d), Mycoplasma hyopneumoniae and Lawsonia intracellularisis now commercially available.1 It was granted license approval from the USDA in June 2022.1,2
The vaccine is indicated for the inoculation of healthy pigs, aged 3 weeks or older. It is the first ready-to-use, single-dose vaccine for use against disease caused by PCV2a and PCV2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis, according to Merck Animal Health.1,2
In one bottle, veterinarians and producers have the convenience of vaccinating for 3 of the most important swine disease concerns, with no mixing or reconstituting.1 “This vaccine complements the existing [Merck Animal Health] product portfolio, providing swine veterinarians and producers with the additional option of vaccinating against disease caused by PCV2a and PCV2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis,” said Jamie Lehman, DVM, swine technical services veterinarian, Merck Animal Health, in an organizational release.1,2
The new vaccine isavailablein100-and500-mlvials.1 It is administered by intramuscular injection of 2 m per dose.3
According to Merck, the duration of immunity for PCV2d is at least 16 weeks, the duration for immunity for Mycoplasma hyopneumoniae is at least 10 weeks, and the duration of immunity for ileitis caused by Lawsonia intracellularis is at least 20 weeks. The duration of immunity for PCV2a has not been established.2,3